In cellular and animal studies, both the full-length BAI1 and its proteolytically released extracellular domains have been showed to exhibit multifaceted bioactivity, including inhibition of angiogenesis, suppression of tumor progression, and modulation of immune responses via interactions with CD36, integrins, lipopolysaccharide (LPS), and phosphatidylserine (PtdSer). The gene discussed is ADGRB1; the disease is neoplasm.